Reply to F. Conforti et al

Affiliations

¹ Kathy Pan, MD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Linda Bosserman, MD, City of Hope National Medical Center, Duarte, CA; and Rowan T. Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.

Comment

Kathy Pan et al. J Clin Oncol. 2019.

. 2019 Jul 20;37(21):1840-1841.

doi: 10.1200/JCO.19.01133. Epub 2019 Jun 7.

¹ Kathy Pan, MD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Linda Bosserman, MD, City of Hope National Medical Center, Duarte, CA; and Rowan T. Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.

No abstract available

Comment on

Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Pan K, Bosserman LD, Chlebowski RT. Pan K, et al. J Clin Oncol. 2019 Apr 10;37(11):858-861. doi: 10.1200/JCO.18.01360. Epub 2019 Feb 11. J Clin Oncol. 2019. PMID: 30742565 No abstract available.
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
Conforti F, Pala L. Conforti F, et al. J Clin Oncol. 2019 Jul 20;37(21):1838-1840. doi: 10.1200/JCO.19.00559. Epub 2019 Jun 7. J Clin Oncol. 2019. PMID: 31173554 Free PMC article. No abstract available.